Concepedia

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

Katrina S. Pedersen, Patrick Grierson, Joel Picus, A. Craig Lockhart, Bruce J. Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang,

Investigational New Drugs · 2021 · 33 citations · 16 references

DOI

Concepts

References

16

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

, , +11

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

, , +12

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers et al. · Cancer Cell · 2005 · 1.6K citations · Full text

, , +16

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 943 citations · Full text

, , +14

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2008 · 908 citations · Full text

, , +10